AP

Apyx Medical CorpNASDAQ APYX Stock Report

Last reporting period 30 Sep, 2024

Updated 22 Nov, 2024

Last price

Market cap $B

0.041

Micro

Exchange

XNAS - Nasdaq

APYX Stock Analysis

AP

Uncovered

Apyx Medical Corp is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-42/100

Low score

Market cap $B

0.041

Dividend yield

Shares outstanding

34.598 B

Apyx Medical Corp. operates as an energy-based medical technology company. The company is headquartered in Clearwater, Florida and currently employs 276 full-time employees. The firm operates through two segments: Advanced Energy and original equipment manufacturer (OEM). Its Advanced Energy product portfolio consists of its Helium Plasma Technology that is marketed and sold as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market. These product lines consist of a multifunction generator, a handpiece, and a supply of helium gas. Its primary focus is on the cosmetic surgery market, where Renuvion offers plastic surgeons, fascial plastic surgeons and cosmetic physicians the ability to provide controlled heat to the tissue to achieve their desired results. The firm designs, develops, and manufactures electrosurgical equipment by producing generators and related accessories for medical device manufacturers through original equipment manufacturing (OEM) agreements, as well as start-up companies with the need for its energy-based designs.

View Section: Eyestock Rating